Ritter Pharmaceuticals (RTTR) vs. Nexvet Biopharma plc (NVET) Critical Survey

Ritter Pharmaceuticals (NASDAQ: RTTR) and Nexvet Biopharma plc (NASDAQ:NVET) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Insider & Institutional Ownership

2.2% of Ritter Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.4% of Nexvet Biopharma plc shares are owned by institutional investors. 30.4% of Ritter Pharmaceuticals shares are owned by company insiders. Comparatively, 37.0% of Nexvet Biopharma plc shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for Ritter Pharmaceuticals and Nexvet Biopharma plc, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ritter Pharmaceuticals 0 1 5 0 2.83
Nexvet Biopharma plc 0 1 0 0 2.00

Ritter Pharmaceuticals presently has a consensus target price of $3.40, indicating a potential upside of 900.00%. Nexvet Biopharma plc has a consensus target price of $6.72, indicating a potential upside of 0.00%. Given Ritter Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Ritter Pharmaceuticals is more favorable than Nexvet Biopharma plc.

Earnings and Valuation

This table compares Ritter Pharmaceuticals and Nexvet Biopharma plc’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Ritter Pharmaceuticals N/A N/A -$18.38 million ($1.16) -0.29
Nexvet Biopharma plc N/A N/A N/A ($1.75) -3.84

Nexvet Biopharma plc is trading at a lower price-to-earnings ratio than Ritter Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ritter Pharmaceuticals and Nexvet Biopharma plc’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ritter Pharmaceuticals N/A -480.51% -235.87%
Nexvet Biopharma plc N/A -102.72% -89.82%

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

About Nexvet Biopharma plc

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply